In contrast, a study using panels of CDK4/6i and MDM2i to treat preclinical models of neuroblastoma (68), and a study that combined the MDM2i nutlin-3A with various CDK4/6i in sarcoma cell lines (69), found no evidence of synergy between MDM2i and CDK4/6i. The gene discussed is CDK4; the disease is sarcoma.